Role of the pharmacist

Pharmacotherapy

Volumn 26, Issue 12 II, 2006, Pages

  Bottorff, Michael ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cardiometabolic risk factors; Compliance; Drug management programs; Pharmacists

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; SIBUTRAMINE; STATINE DERIVATIVE;

BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; HEALTH PRACTITIONER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACIST; PREVALENCE; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SINGLE DRUG DOSE;

EID: 33845247816     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12part2.227s     Document Type: Conference Paper

References (21)

1. Centers for Disease Control and Prevention. Declining prevalence of no known major risk factors for heart disease and stroke among adults - United States, 1991-2001. MMWR Weekly 2004;53(0I):4-7. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5301a2.htm. Accessed June 15, 2006.
2. Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209.
3. Walford H, Ha MA. Obesity in the east of England. Eastern region public health observatory. Cambridge, United Kingdom: Institute of Public Health, 2004.
4. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151:I85-91.
5. Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005;112:1651-62.
6. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005;61:667-74.
7. Davidson MH, Maki KC, Pearson TA, et al. Results of the national cholesterol education (NCEP) program evaluation project utilizing novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol 2005;96:556-63.
8. Joslin EP. Arteriosclerosis and diabetes. Ann Clin Med 1927;5:1061.
9. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353(20):2111-20.
10. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
11. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
12. Cannon CP, Steinberg BA, Murphy SA, Mega JL Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
13. Ito MK. Role of the pharmacist in establishing lipid intervention programs. Pharmacotherapy 2003;23(9 pt 2):41S-7.
14. Ali F, Laurin MY, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003;10(3):101-6.
15. Lee SS, Cheung PP, Chow MS. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. J Clin Pharmacol 2004;44:632-9.
16. Ragucci KR, Fermo JD, Wessell AM, Chumney ECG. Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy 2005;25(12):1809-16.
17. Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation 2005;112:924-34.
18. American Association of Colleges of Pharmacy. Letter to Centers for Medicare and Medicaid Services. Available from http://www.aacp.org/Docs/ MainNavigation/Resources/6308_MTMServicesDefinitionandProgramCriteria27-Jul-04. pdf. Accessed October 5, 2006.
19. Consensus Document Workgroup. Sound medication therapy management programs. J Manag Care Pharm 2006;12(3 suppl):S2-13.
20. Centers for Medicare and Medicaid Services. Prescription drug coverage - general information. Available from http://www.cms.hhs.gov/ PrescriptionDrugCovGenIn/. Accessed June 25, 2006.
21. American Pharmacists Association. Understanding Medicare reform: what pharmacists need to know. Monograph 2: medication therapy management services and chronic care improvement programs. 2004. Available from http://www.aphanet. org/AM/Template.cfm?Section=Search§ion=General_Patient_Resources& template=/CM/ContentDisplay.cfm&ContentFileID=730. Accessed August 7, 2006.